Merck to Present New Data on Mavenclad®, Rebif® and the Investigational Therapy Evobrutinib at the AAN Annual Meeting 2019
Not intended for U.S. or U.K. based media - 20 abstracts will be presented during the AAN Annual Meeting 2019 to demonstrate Merck's commitment and clinical development program in multiple sclerosis Darmstadt, Germany (ots/PRNewswire) - Merck, a leading science and technology company, today announced that data from ...
plus